Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortex

Neurochemistry International

Volumn 58, Issue 1, 2011, Pages 78-84

  Rollema, Hans ^a   Wilson, Gary G ^a   Lee, Theodore C ^a   Folgering, Joost H A ^b   Flik, Gunnar ^b  

^a PFIZER INC   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Antidepressants; Microdialysis; Monoamine release; Serotonin syndrome; Varenicline

Indexed keywords

CLORGYLINE; DOPAMINE; NORADRENALIN; SEROTONIN; SERTRALINE; VARENICLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG EFFECT; EXTRACELLULAR FLUID; IN VITRO STUDY; MALE; MICRODIALYSIS; MONOAMINE RELEASE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SEROTONIN SYNDROME;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZAZEPINES; BIOGENIC MONOAMINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLORGYLINE; DATA INTERPRETATION, STATISTICAL; DOPAMINE; DRUG INTERACTIONS; EXTRACELLULAR SPACE; MALE; MICRODIALYSIS; MONOAMINE OXIDASE INHIBITORS; NEUROTRANSMITTER AGENTS; NICOTINIC AGONISTS; NOREPINEPHRINE; PREFRONTAL CORTEX; QUINOXALINES; RATS; RATS, WISTAR; SEROTONIN; SERTRALINE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

RATTUS;

EID: 78650415664     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.10.015     Document Type: Article

References (44)

1. F. Artigas, and A. Adell The use of brain microdialysis in antidepressant drug research B. Westerink, T.I.F.H. Cremers, Handbook of Microdialysis 2007 Academic Press 527 544
2. H.J. Aubin, A. Bobak, J.R. Britton, C. Oncken, C.B. Billing Jr., J. Gong, K.E. Williams, and K.R. Reeves Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial Thorax 63 2008 717 724
3. E.W. Boyer, and M. Shannon The serotonin syndrome N. Engl. J. Med. 352 2005 1112 1120
4. N. Breslau, E.L. Peterson, L.R. Schultz, H.D. Chilcoat, and P. Andreski Major depression and stages of smoking. A longitudinal investigation Arch. Gen. Psychiatry 55 1998 161 166
5. A.H. Burstein, D.J. Clark, M. O'Gorman, S.A. Willavize, T.G. Brayman, G.S. Grover, R.L. Walsky, R.S. Obach, and H.M. Faessel Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study J. Clin. Pharmacol. 47 2007 1421 1429
6. K. Cahill, L.F. Stead, and T. Lancaster Nicotine receptor partial agonists for smoking cessation Cochrane Database Syst. Rev. 2007 CD006103
7. A. Cipriani, T.A. Furukawa, G. Salanti, J.R. Geddes, J.P. Higgins, R. Churchill, N. Watanabe, A. Nakagawa, I.M. Omori, H. McGuire, M. Tansella, and C. Barbui Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis Lancet 373 2009 746 758
8. J.W. Coe, P.R. Brooks, M.G. Vetelino, M.C. Wirtz, E.P. Arnold, J. Huang, S.B. Sands, T.I. Davis, L.A. Lebel, C.B. Fox, A. Shrikhande, J.H. Heym, E. Schaeffer, H. Rollema, Y. Lu, R.S. Mansbach, L.K. Chambers, C.C. Rovetti, D.W. Schulz, F.D. Tingley III, and B.T. O'Neill Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation J. Med. Chem. 48 2005 3474 3477
9. P. Cuijpers, F. Smit, M. ten Have, and R. de Graaf Smoking is associated with first-ever incidence of mental disorders: a prospective population-based study Addiction 102 2007 1303 1309
10. H.M. Faessel, R.S. Obach, H. Rollema, P. Ravva, and A.H. Burstein A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation Clin. Pharmacokinetics 49 2010 799 816
11. J.D. Fryer, and R.J. Lukas Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function J. Neurochem. 72 1999 1117 1124
12. P.K. Gillman A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action Biol. Psychiatry 59 2006 1046 1051
13. B. Grant, D. Hasin, S. Chou, F. Stinson, and D. Dawson Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions Arch. Gen. Psychiatry 61 2004 1107 1115 (Pubitemid 39463411)
14. E.C. Hennings, J.P. Kiss, K. De Oliveira, P.T. Toth, and E.S. Vizi Nicotinic acetylcholine receptor antagonistic activity of monoamine uptake blockers in rat hippocampal slices J. Neurochem. 73 1999 1043 1050
15. J. Johannson, and R. Hill Serotonin syndrome following varenicline use Drug Saf. 32 2009 932
16. D. Kalman, S.B. Morissette, and T.P. George Co-morbidity of smoking in patients with psychiatric and substance use disorders Am. J. Addict. 14 2005 106 123
17. T. Kinnunen, A. Haukkala, T. Korhonen, Z.N. Quiles, A. Spiro III, and A.J. Garvey Depression and smoking across 25 years of the Normative Aging Study Int. J. Psychiatry Med. 36 2006 413 426
18. T. Klein, C.M. Hofland, E. Dremencov, and T.I.F.H. Cremers SymDAQ derivatization for single-run profiling of MA and AA in microdialysate, plasma and cerebrospinal fluid by LC-MS/MS Soc. Neuroscience Abstr. 2009 FF95
19. O. Klungsøyr, J.F. Nygrd, T. Sørensen, and I. Sandanger Cigarette smoking and incidence of first depressive episode: an 11-year, population-based follow-up study Am. J. Epidemiol. 163 2006 421 432
20. T. Korhonen, U. Broms, J. Varjonen, K. Romanov, M. Koskenvuo, T. Kinnunen, and J. Kaprio Smoking behaviour as a predictor of depression among Finnish men and women: a prospective cohort study of adult twins Psychol. Med. 37 2007 705 715
21. K. Lasser, J.W. Boyd, S. Woolhandler, D.U. Himmelstein, D. McCormick, and D.H. Bor Smoking and mental illness: a population-based prevalence study JAMA 284 2000 2606 2610
22. S. Lipper, D.L. Murphy, S. Slater, and M.S. Buchsbaum Comparative behavioral effects of clorgyline and pargyline in man: a preliminary evaluation Psychopharmacology (Berl.) 62 1979 123 128
23. R.S. Obach, A.E. Reed-Hagen, S.S. Krueger, J. Beth, B.J. Obach, T.N. O'Connell, K.S. Zandi, S. Miller, and J.W. Coe Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro Drug. Metab. Disp. 34 2006 121 130
24. K.N. Paperwalla, T.T. Levin, J. Weiner, and S.M. Saravay Smoking and depression Med. Clin. North Am. 88 2004 1483 1494 x-xi
25. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 1982 Academic Press San Diego
26. Pfizer Inc., 2007. A study of the efficacy and safety of varenicline in Japanese smokers motivated to quit smoking.
27. M.R. Picciotto, N.A. Addy, Y.S. Mineur, and D.H. Brunzell It is not "either/or": activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood Prog. Neurobiol. 84 2008 329 342
28. H. Rollema, L.K. Chambers, J.W. Coe, J. Glowa, R.S. Hurst, L.A. Lebel, Y. Lu, R.S. Mansbach, R.J. Mather, C.C. Rovetti, S.B. Sands, E. Schaeffer, D.W. Schulz, F.D. Tingley III, and K.E. Williams Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid Neuropharmacology 52 2007 985 994
29. H. Rollema, V. Guanowsky, Y.S. Mineur, A. Shrikhande, J.W. Coe, P.A. Seymour, and M.R. Picciotto Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect Eur. J. Pharmacol. 605 2009 114 116
30. H. Rollema, M. Hajós, P.A. Seymour, R. Kozak, M.J. Majchrzak, V. Guanowsky, W.E. Horner, D.S. Chapin, W.E. Hoffmann, D.E. Johnson, S. McLean, J. Freeman, and K.E. Williams Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition Biochem. Pharmacol. 78 2009 813 824
31. D.S. Segal, R. Kuczenski, and C. Okuda Clorgyline-induced increases in presynaptic DA: changes in the behavioral and neurochemical effects of amphetamine using in vivo microdialysis Pharmacol. Biochem. Behav. 42 1992 421 429
32. K. Shioda, K. Nisijima, T. Yoshino, and S. Kato Extracellular serotonin, dopamine and glutamate levels are elevated in the hypothalamus in a serotonin syndrome animal model induced by tranylcypromine and fluoxetine Prog. Neuropsychopharmacol. Biol. Psychiatry 28 2004 633 640
33. R.D. Shytle, A.A. Silver, R.J. Lukas, M.B. Newman, D.V. Sheehan, and P.R. Sanberg Nicotinic acetylcholine receptors as targets for antidepressants Mol. Psychiatry 7 2002 525 535
34. D.A. Slattery, A.L. Hudson, and D.J. Nutt Invited review: the evolution of antidepressant mechanisms Fundam. Clin. Pharmacol. 18 2004 1 21
35. J. Sprouse, T. Clarke, L. Reynolds, J. Heym, and H. Rollema Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo Neuropsychopharmacology 14 1996 225 231
36. C. Sun-Edelstein, S.J. Tepper, and R.E. Shapiro Drug-induced serotonin syndrome: a review Expert. Opin. Drug Saf. 7 2008 587 596
37. B.K. Szasz, E.S. Vizi, and J.P. Kiss Nicotinic acetylcholine receptor antagonistic property of the selective dopamine uptake inhibitor, GBR-12909 in rat hippocampal slices Neuroscience 145 2007 344 349
38. S. Tonstad, S. Davies, M. Flammer, C. Russ, and J. Hughes Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis Drug Saf. 33 2010 289 301
39. S. Tonstad, P. Tønnesen, P. Hajek, K.E. Williams, C.B. Billing, K.R. Reeves Varenicline Phase 3 Study Group Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial JAMA 296 2006 64 71
40. L.M. Tremaine, W.M. Welch, and R.A. Ronfeld Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog Drug Metab. Dispos. 17 1989 542 550
41. T.B. Üstün, J.L. Ayuso-Mateos, S. Chatterji, C. Mathers, and C.J. Murray Global burden of depressive disorders in the year 2000 Br. J. Psychiatry 184 2004 386 392
42. P.C. Waldmeier, A. Delini-Stula, and L. Maître Preferential deamination of dopamine by an A type monoamine oxidase in rat brain Naunyn Schmiedebergs Arch. Pharmacol. 292 1976 9 14
43. World Health Organization WHO Report on the Global Tobacco Epidemic: The MPOWER Package 2008 World Health Organization Geneva
44. D. Ziedonis, B. Hitsman, J.C. Beckham, M. Zvolensky, L.E. Adler, J. Audrain-McGovern, N. Breslau, R.A. Brown, T.P. George, J. Williams, P.S. Calhoun, and W.T. Riley Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report Nicotine Tob. Res. 10 2008 1691 1715